Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials.

MLA

Lv, Yingge, et al. “Anlotinib and Anti-PD-1 MAbs Perfected CIK Cell Therapy for Lung Adenocarcinoma in Preclinical Trials.” Journal of Leukocyte Biology, vol. 116, no. 3, Sept. 2024, pp. 544–54. EBSCOhost, https://doi.org/10.1093/jleuko/qiae037.

APA

Lv, Y., Zhao, H., Liu, S., Meng, Y., Yu, W., Liu, T., Sun, Q., Shen, M., Ren, X., & Liu, L. (2024). Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials. Journal of Leukocyte Biology, 116(3), 544–554. https://doi.org/10.1093/jleuko/qiae037

Chicago

Lv, Yingge, Hua Zhao, Shaochuan Liu, Yuan Meng, Wenwen Yu, Ting Liu, Qian Sun, Meng Shen, Xiubao Ren, and Liang Liu. 2024. “Anlotinib and Anti-PD-1 MAbs Perfected CIK Cell Therapy for Lung Adenocarcinoma in Preclinical Trials.” Journal of Leukocyte Biology 116 (3): 544–54. doi:10.1093/jleuko/qiae037.